# Clinical study of 15 cases of primary non-immunodeficient central nervous system lymphoma in children

## TL;DR

This paper studies 15 children with non-immunodeficient central nervous system lymphoma, focusing on clinical features and treatment outcomes using high-dose methotrexate-based chemotherapy.

## Contribution

The study provides insights into the clinical management and treatment effectiveness of pediatric non-immunodeficient central nervous system lymphoma.

## Key findings

- High-dose methotrexate-based chemotherapy shows good overall prognosis in children with non-immunodeficient PCNSL.
- Children with stable disease after initial treatment may not require maintenance therapy.
- Re-treatment with high-dose methotrexate remains effective for relapsed or progressive cases.

## Abstract

回顾性分析首都医科大学附属北京儿童医院2013年5月至2023年5月收治年龄≤18岁的15例非免疫缺陷原发中枢神经系统淋巴瘤（PCNSL）患儿的临床资料，总结临床特点以及基于病理组织亚型的、以大剂量甲氨蝶呤（HD-MTX）为基础的化疗方案的治疗效果。男女比例2.7∶1，中位确诊年龄7.2（2.3～16.4）岁，临床首发症状以颅高压伴颅神经受损为主，影像学以多发病灶为主。免疫功能正常的儿童PCNSL发病率极低，以HD-MTX为基础的化疗整体预后良好，部分病情评估稳定者可减量维持或不予维持治疗。初治以非HD-MTX为主的化疗，病情进展或复发患儿再次予HD-MTX为基础的化疗仍有效。